Dyne Therapeutics
90 hedge funds and large institutions have $321M invested in Dyne Therapeutics in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 27 increasing their positions, 31 reducing their positions, and 11 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
2.29% less ownership
Funds ownership: 92.68% → 90.39% (-2.3%)
5% less funds holding
Funds holding: 95 → 90 (-5)
13% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 31
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
30% less capital invested
Capital invested by funds: $458M → $321M (-$137M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$3.92M |
| 2 |
Citigroup
New York
|
+$2.72M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$1.14M |
| 4 |
BlackRock
New York
|
+$754K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$705K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$5.78M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$5.06M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.59M |
| 4 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$3.25M |
| 5 |
CC
Commodore Capital
New York
|
-$2.94M |
DYN Hedge Fund Activity: Q2 2022 in Review
90 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q2 2022, worth a combined $321M — down 30% from $458M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of DYN and 8 opened new positions — a net loss of 3 holders — while 31 trimmed existing stakes and 27 added.
The largest buyer was Franklin Resources, adding an estimated $3.92M. The largest seller was Norges Bank, exiting entirely with an estimated $5.78M sold.
- 90 institutional investors held Dyne Therapeutics (DYN) as of Q2 2022, down from 95 in Q1 2022.
- Funds reported $321M of Dyne Therapeutics stock for Q2 2022, down 30% quarter-over-quarter.
- 8 funds opened new Dyne Therapeutics positions in Q2 2022 and 11 closed out, a net change of -3 holders.
- The largest Dyne Therapeutics buyer in Q2 2022 was Franklin Resources, an estimated $3.92M added.
- The largest Dyne Therapeutics seller in Q2 2022 was Norges Bank, an estimated $5.78M sold.
Based on aggregated 13F filings for Q2 2022.